Edmund Liang Chai Ong, Speaker at Infectious Diseases Conferences
Physician

Edmund Liang Chai Ong

Newcastle University Medicine Malaysia, Malaysia

Abstract:

Recent advances have reshaped tuberculosis (TB) care for people living with HIV (PLHIV), shortening treatment, improving outcomes, and simplifying programmatic delivery. For drug-resistant TB, the World Health Organization now recommends all-oral, 6-month regimens based on bedaquiline, pretomanid, and linezolid with moxifloxacin when eligible (BPaLM) or without moxifloxacin (BPaL), which demonstrate noninferior—or superior—effectiveness with improved tolerability versus longer historical regimens, offering substantial benefits in adherence for PLHIV who face complex polypharmacy.

For drug-susceptible pulmonary TB, the 4-month rifapentine-moxifloxacin regimen from TB Trials Consortium Study 31/A5349 is noninferior to the 6-month standard, including in participants with HIV, and is increasingly informing guideline uptake where drug–drug interactions can be managed.

TB preventive treatment has also accelerated: short-course rifapentine-isoniazid options—weekly for 3 months (3HP) and daily for 1 month (1HP)—are effective, safe, and better completed by PLHIV than longer isoniazid monotherapy, enabling broader scale-up alongside antiretroviral therapy (ART).

Optimizing HIV–TB co-treatment remains critical. Early ART initiation—ideally within 2 weeks of starting TB therapy regardless of CD4 count—reduces mortality, with caution for TB meningitis. Concurrently, integrase inhibitor–based ART is preferred, but rifampicin necessitates dose adjustments; dolutegravir should be given twice daily during rifampicin therapy to maintain therapeutic exposure. Programs are evaluating operational strategies to support this temporary dose change.

Collectively, shorter, all-oral TB regimens, scalable preventive therapy, and harmonized ART co-administration mark a step-change for PLHIV, promising higher treatment completion, fewer adverse events, and reduced transmission when coupled with timely diagnosis and robust pharmacovigilance.

Biography:

Professor Edmund L. C. Ong is an Infectious Diseases physician and academic who graduated from the University of Newcastle Medical School, UK, and undertook specialist training in Infectious Diseases, Tropical Medicine and General Internal Medicine in the United Kingdom. He is currently a Visiting Professor in Practice at Newcastle University Medicine Malaysia.

His clinical and research interests encompass opportunistic infections, HIV, tuberculosis, dengue and other tropical infections, the evaluation of anti-infective agents, clinical epidemiology, and innovation in healthcare quality improvement and clinical audit.

Professor Ong has served as Principal Investigator and collaborator in numerous international research projects involving HIV, tuberculosis and dengue, with research and clinical collaborations spanning Nigeria, South Africa, Myanmar and Malaysia. He has contributed to several textbooks on infectious diseases and has authored or co-authored more than 200 publications in peer-reviewed scientific journals.

He serves on the editorial boards of several scientific journals, including Tropical Medicine and Infectious Disease and Advances in Medicine and Health Sciences. He is also an experienced examiner for undergraduate and postgraduate medical examinations, including MRCP(UK), the Diploma in HIV Medicine and Master of Medicine (MMed) programmes.

His professional leadership includes serving as International Global Advisor (Malaysia) to the Royal College of Physicians, London, and as former Chair of the British HIV Association (BHIVA) Audit and Standards of Care Committee. He remains actively involved in international medical education, research collaboration and the advancement of clinical standards in infectious diseases.

WhatsApp
Top